AbbVie Inc Total Assets
AbbVie Inc total assets. Based on the latest financial reports, AbbVie Inc (ABBV) holds total assets worth $136.46 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AbbVie Inc market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of AbbVie Inc (2010–2025)
Total assets of AbbVie Inc from 2010 to 2025. This chart illustrates how AbbVie Inc's total assets have evolved over time, based on quarterly financial data. See ABBV stock price and chart for real-time trading data and today's change.
AbbVie Inc - Asset Composition Analysis
AbbVie Inc Total Assets Breakdown (December 2025)
AbbVie Inc total assets breakdown as of December 2025. AbbVie Inc's total assets of $136.46 Billion consist of 21.7% current assets and 78.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.9% |
| Accounts Receivable | $12.59 Billion | 9.4% |
| Inventory | $4.95 Billion | 3.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $52.64 Billion | 39.3% |
| Goodwill | $35.64 Billion | 26.6% |
Asset Composition Trend (2010–2025)
This chart illustrates how AbbVie Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore AbbVie Inc (ABBV) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AbbVie Inc's current assets represent 21.7% of total assets in 2025, a decrease from 38.9% in 2010.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2025, up from 0.1% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 65.0% of total assets, an increase from 46.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 39.3% of total assets.
AbbVie Inc Competitors by Total Assets
Key competitors of AbbVie Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096
|
China | CN¥3.80 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
|
Roche Holding AG
SW:ROG
|
Switzerland | CHF100.70 Billion |
|
Sanofi
F:SNW2
|
Germany | €129.79 Billion |
|
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422
|
China | CN¥41.49 Billion |
|
Grifols S.A
F:G0FB
|
Germany | €19.71 Billion |
|
TTK Healthcare Limited
NSE:TTKHLTCARE
|
India | Rs13.29 Billion |
|
Eli Lilly and Company
NYSE:LLY
|
USA | $142.28 Billion |
AbbVie Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.80 | 0.76 | 0.91 |
| Quick Ratio | 0.68 | 0.64 | 0.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.57 Billion | $-8.73 Billion | $-2.69 Billion |
AbbVie Inc - Advanced Valuation Insights
This section examines the relationship between AbbVie Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 50.46 |
| Latest Market Cap to Assets Ratio | 2.66 |
| Asset Growth Rate (YoY) | -0.9% |
| Total Assets | $133.96 Billion |
| Market Capitalization | $356.49 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values AbbVie Inc's assets at a significant premium (2.66x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: AbbVie Inc's assets decreased by 0.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for AbbVie Inc (2010–2025)
The table below shows the annual total assets of AbbVie Inc from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $133.96 Billion | -0.89% |
| 2024-12-31 | $135.16 Billion | +0.33% |
| 2023-12-31 | $134.71 Billion | -2.95% |
| 2022-12-31 | $138.81 Billion | -5.27% |
| 2021-12-31 | $146.53 Billion | -2.68% |
| 2020-12-31 | $150.56 Billion | +68.96% |
| 2019-12-31 | $89.11 Billion | +50.15% |
| 2018-12-31 | $59.35 Billion | -16.15% |
| 2017-12-31 | $70.79 Billion | +7.09% |
| 2016-12-31 | $66.10 Billion | +24.60% |
| 2015-12-31 | $53.05 Billion | +92.82% |
| 2014-12-31 | $27.51 Billion | -5.77% |
| 2013-12-31 | $29.20 Billion | +8.11% |
| 2012-12-31 | $27.01 Billion | +38.35% |
| 2011-12-31 | $19.52 Billion | -7.64% |
| 2010-12-31 | $21.13 Billion | -- |
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various c… Read more